PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
2.36%
Cash & equivalents growing 2.36% while AVXL's declined -3.05%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
2.36%
Below half of AVXL's -3.05%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.66%
Other current assets growth < half of AVXL's 77.91%. David Dodd sees a leaner approach to short-term items.
1.99%
Below half of AVXL's -2.40%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-7.06%
Both AVXL and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both AVXL and the company show zero Long-Term Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.24%
Both AVXL and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
1.71%
Below half of AVXL's -2.24%. Michael Burry sees a potential red flag for stagnation or capital shortage.
22.15%
Less than half of AVXL's -13.19%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both AVXL and the company show zero Deferred Revenue (Current) Growth.
No Data
No Data available this quarter, please select a different quarter.
20.63%
Less than half of AVXL's -23.51%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Higher Deferred Tax Liabilities (Non-Current) Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-0.37%
Less than half of AVXL's -32.54%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
3.44%
Less than half of AVXL's -23.51%. David Dodd sees far fewer liability expansions relative to competitor.
6.90%
Above 1.5x AVXL's 2.44%. Michael Burry suspects heavy new equity expansion or dilution.
-3.28%
Similar yoy to AVXL's -3.50%. Walter Schloss sees parallel earnings retention vs. competitor.
100.00%
Less than half of AVXL's -411657153439334272.00%. David Dodd sees fewer intangible or market-driven swings than competitor.
-100.00%
Higher Other Stockholders' Equity Items Growth compared to AVXL's zero value, indicating worse performance.
-0.05%
Below half AVXL's -0.28%. Michael Burry sees potential underperformance in building shareholder capital.
1.71%
Below half AVXL's -2.24%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
0.63%
Higher Total Investments Growth compared to AVXL's zero value, indicating better performance.
-6.71%
Higher Total Debt Growth compared to AVXL's zero value, indicating worse performance.
-2.57%
Less than half of AVXL's 3.05%. David Dodd sees better deleveraging or stronger cash buildup than competitor.